Related references
Note: Only part of the references are listed.Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Serena Di Cosimo et al.
CLINICAL CANCER RESEARCH (2019)
The latest progress on miR-374 and its functional implications in physiological and pathological processes
Hongjun Bian et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Current and future perspectives of liquid biopsies in genomics-driven oncology
Ellen Heitzer et al.
NATURE REVIEWS GENETICS (2019)
Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage
Hao Wang et al.
CLINICAL EPIGENETICS (2018)
miRWalk: An online resource for prediction of microRNA binding sites
Carsten Sticht et al.
PLOS ONE (2018)
Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer
Chaoran Yu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2018)
Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers
Rimi Hamam et al.
CELL DEATH & DISEASE (2017)
MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer
Xin Xu et al.
ONCOTARGET (2016)
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer
Debora de Melo Gagliato et al.
ONCOTARGET (2016)
A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
F. Du et al.
SCIENTIFIC REPORTS (2016)
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model
Michael D. Curley et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression
Q. Xu et al.
ONCOGENE (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2015)
MicroRNA biogenesis pathways in cancer
Shuibin Lin et al.
NATURE REVIEWS CANCER (2015)
NqA: An R-based algorithm for the normalization and analysis of microRNA quantitative real-time polymerase chain reaction data
Paolo Verderio et al.
ANALYTICAL BIOCHEMISTRY (2014)
MicroRNAs in Cancer
Gianpiero Di Leva et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)
GPER mediated estradiol reduces miR-148a to promote HLA-G expression in breast cancer
Sifeng Tao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial
Volkmar Mueller et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Molecular Pathways: microRNAs, Cancer Cells, and Microenvironment
Ioana Berindan-Neagoe et al.
CLINICAL CANCER RESEARCH (2014)
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1
Qing Xu et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2013)
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
S. Guiu et al.
JOURNAL OF ONCOLOGY (2013)
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Eun-Jung Jung et al.
CANCER (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
Francoise Rothe et al.
PLOS ONE (2011)
MiR-148a inhibits angiogenesis by targeting ERBB3
Jing Yu et al.
JOURNAL OF BIOMEDICAL RESEARCH (2011)
Role of Cyclic AMP Response Element-Binding Protein in Insulin-like Growth Factor-I Receptor Up-regulation by Sex Steroids in Prostate Cancer Cells
Marco Genua et al.
CANCER RESEARCH (2009)
Steroid receptor regulation of epidermal growth factor signaling through src in breast and prostate cancer cells: Steroid antagonist action
A Migliaccio et al.
CANCER RESEARCH (2005)
Regulation of life and death by the zinc finger transcription factor Egr-1
G Thiel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Share Paper
